Aegerion wins Health Canada OK for Juxtapid in HoFH
This article was originally published in Scrip
Executive Summary
Canadian regulatory officials granted approval to Aegerion Pharmaceuticals to market Juxtapid (lomitapide), a microsomal triglyceride transfer protein inhibitor, as an adjunct to a low-fat diet and other lipid-lowering drugs, with or without low-density lipoprotein (LDL) apheresis, to reduce LDL cholesterol in adults with homozygous familial hypercholesterolemia (HoFH).